Could a common painkiller boost brain development in preemies?
NCT ID NCT06064825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 500 extremely preterm infants who received paracetamol or placebo in the TREOCAPA trial. Researchers will use a parent questionnaire to assess cognitive development at age 2. The goal is to see if early paracetamol use improves thinking and learning skills in these vulnerable children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- paracetamol (acetaminophen)
- What this could lead to
- If successful, this could show that early paracetamol treatment helps prevent cognitive delays in extremely preterm infants.
- What could go wrong
- This is a follow-up study, not a new treatment trial. Results depend on parent reports, which may not be fully accurate, and the original trial may not show a clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATENCY OF THE DUCTUS ARTERIOSUS ACETAMINOPHEN EXTREME PREMATURITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU d'Angers
RECRUITINGAngers, France
-
CHU de Montpellier
RECRUITINGMontpellier, France
-
CHU de Nantes
RECRUITINGNantes, France
-
CHU de Strasbourg
RECRUITINGStrasbourg, France
-
CHU de Tours
RECRUITINGTours, France
-
Cochin - APHP
RECRUITINGParis, France
-
Hopital Robert Debré
RECRUITINGParis, France
-
Hôpital Femme Mère Enfant
RECRUITINGBron, France